COMMUNIQUÉS West-GlobeNewswire

IBA – ACQUISITION OF OWN SHARES
10/02/2026
Louvain-la-Neuve, Belgium, February 10 th , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA [...]
BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart
10/02/2026
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it [...]
Tecan to host Analyst and Media Conference with Capital Markets Update on March 16, 2026
10/02/2026
Männedorf, Switzerland, February 10, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) will hold an Analyst and Media Conference on Monday, March 16, 2026, at 2:00 pm CET to present its full-year 2025 financial results [...]
IBA – ACQUISITION D’ACTIONS PROPRES
10/02/2026
Louvain-la-Neuve, Belgique, 10 février 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
Press Release: Sanofi completes the acquisition of Dynavax
10/02/2026
Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition includes Dynavax’s adult [...]
MedWell Ai Executes Letter Of Intent To Create America's First Vertically Integrated Regenerative Wellness Eco-System
10/02/2026
CLEARWATER, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- via IBN – MedWell Ai, Inc ("Company") (OTCQB: MWAI) is pleased to announce the signing of a Letter of Intent (“LOI”) to create a vertically integrated health, wellness [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 janvier 2026
10/02/2026
Nombre total de droits de vote et d’actions composant le capital social au 31 janvier 2026 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
10/02/2026
WHO recognition of “etaroleucel” (CELZ-101) builds on prior “olastrocel” (CELZ-201) milestone, reinforcing platform credibility and supporting multi-program execution PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Creative [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2026
10/02/2026
Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2026 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Trinity Biotech Glucose Monitoring Innovation Achieves Unique Global Recognition: Diabetes Care Premier Hb9210™ HbA1c Analyser Becomes the Only System Awarded Prestigious IFCC Gold Classification for 2026
10/02/2026
– Reinforces Trinity Biotech’s growing position as a key player in diabetes care innovation – Senior commercial executives of Trinity Biotech are attending the World Health Expo from February 10-12, 2026 DUBLIN, Ireland [...]
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
10/02/2026
Additional exchange listing expected to increase token access and contribute to expanded secondary market liquidity for RAIN Nes-Ziona, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV [...]
IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share
10/02/2026
Reports record revenue of $22.7 million for the fourth quarter of 2025, an increase of $3.3 million, or 17%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.50 and non-GAAP diluted EPS of $0. [...]
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
10/02/2026
Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its [...]
Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business
10/02/2026
Oak Ridge, TN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced its intention to transition its primary regulatory reporting [...]
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
10/02/2026
The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse prevention (AURr) [...]
Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas
10/02/2026
Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and mid-to high-single- [...]
Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephology (JASN)
10/02/2026
MediBeacon ® Transdermal GFR System is a first-in-kind product for point of care kidney function assessment Centers of Excellence commercialization in select academic medical centers began in January 2026 ST. LOUIS, Feb [...]
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
10/02/2026
Protocol Expansion Broadens Phase 3 HERO Trial Eligibility Criteria to Include Children Ages 7+ in the United States SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a [...]
Health Canada cannabis guidance exposes “absurd” education gap in healthcare
10/02/2026
- Apothecare calls for medical cannabis education to be integrated into clinical training and standard practice, not left to patients to figure out on their own - TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- New federal [...]

Pages